PATIENTS may not need to make two separate visits to health professionals to receive influenza and COVID-19 vaccines (COVAX) in future, results from a Phase III clinical trial reveals.
While current Australian guidelines require patients to wait 14 days between flu and COVAX shots, the UK-based study conducted by Novavax and Seqirus suggested that the safety and efficacy of both vaccines was retained when co-administered.
In a statement, Novavax President of Research and Development, Gregory Glenn, said the need to receive the vaccines on separate occasions was "burdensome" for patients.
"These results demonstrate the promising opportunity for concomitant vaccination, which may improve the uptake of both vaccines," he said.
The above article was sent to subscribers in Pharmacy Daily's issue from 22 Jun 21
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 22 Jun 21
